

Germany-Wuppertal: Pharmaceutical products

OJ S 144/2023 28/07/2023

Contract notice

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1. Name and addresses

Official name: BARMER

Postal address: Lichtscheider Str. 89

Town: Wuppertal

NUTS code: DEA1 Düsseldorf

Postal code: 42285

Country: Germany

Contact person: BARMER, Abteilung Arzneimittel

E-mail: rabattvertraege@barmer.de**Internet address(es):**Main address: <https://www.rabattvertraege.barmer.de/>Address of the buyer profile: <https://beschaffungen.barmer.de/NetServer/>**I.3. Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at: <https://beschaffungen.barmer.de/NetServer/>

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted to the abovementioned address

I.4. Type of the contracting authority

Body governed by public law

I.5. Main activity

Health

Section II: Object

II.1. Scope of the procurement**II.1.1. Title**

Arzneimittelverträge mit Beitrittsoption - 0050-RVBEITR.63-2023

Reference number: 0050-RVBEITR.63-2023

II.1.2. Main CPV code

33600000 Pharmaceutical products

II.1.3. Type of contract

Supplies

II.1.4. Short description

Die vorliegende Bekanntmachung betrifft nicht die Vergabe eines öffentlichen Auftrages im Sinne der Vergabekoordinierungsrichtlinie (2014/24/EU) bzw. des Kartellrechts. Im Interesse einer möglichst breit angelegten Information der interessierten pharmazeutischen Unternehmer erfolgt diese Bekanntmachung im Supplement zum Amtsblatt der Europäischen Union. Die im Rahmen des vorliegenden Bekanntmachungstextes verwendete Verfahrensbezeichnung "offenes Verfahren" (Ziffer IV.1.1) ist den Vorgaben des Bekanntmachungsformulars geschuldet. Hiermit sowie mit der Nutzung des Mediums "TED" ist keinerlei Unterwerfung unter vergaberechtlicher Regelungen verbunden, deren Geltung kraft Gesetzes bzw. Vergabeverordnungen nicht verpflichtend vorgegeben ist. Es handelt sich um einen Rahmenvertrag mit Beitrittsoption, der sich auf diverse Wirkstoffe bezieht.

II.1.5. Estimated total value

Value excluding VAT: 1,00 EUR

II.1.6. Information about lots

This contract is divided into lots: yes
Tenders may be submitted for all lots

II.2. Description

II.2.1. Title

Bexaroten
Lot No: 1

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland
Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Bexaroten enthalten.

II.2.5. Award criteria

Criteria below
Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025
This contract is subject to renewal: yes
Description of renewals:
Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13.

Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Buserelin (FER_IMP)
Lot No: 2

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland
Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Buserelin in der Darreichungsform Implantat enthalten.

II.2.5. Award criteria

Criteria below
Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025
This contract is subject to renewal: yes
Description of renewals:
Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Casprofungin
Lot No: 3

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Caspofungin enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Cefadroxil (TAB)

Lot No: 4

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Cefadroxil in der Darreichungsform Tablette enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:

no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Dasatinib

Lot No: 5

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Dasatinib enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13.

Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Dasatinib (patentfreie Indikationen)
Lot No: 6

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland
Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Dasatinib in einer patentfreien Indikation enthalten.

II.2.5. Award criteria

Criteria below
Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025
This contract is subject to renewal: yes
Description of renewals:
Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Dexamethason (AMP)
Lot No: 7

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Dexamethason in der Darreichungsform Ampulle enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:

no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Fluorouracil (CRE)

Lot No: 8

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Fluorouracil in der Darreichungsform Creme enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6.

Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:

no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Fluticason furoat und Vilanterol

Lot No: 9

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die die Wirkstoffkombination Fluticason furoat und Vilanterol enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11.

Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Iloprost
Lot No: 10

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland
Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Iloprost enthalten.

II.2.5. Award criteria

Criteria below
Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025
This contract is subject to renewal: yes
Description of renewals:
Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Melatonin (RET, rx)
Lot No: 11

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Melatonin in einer verschreibungspflichtigen, oralen, retardierten Darreichungsform enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information**II.2. Description****II.2.1. Title**

Mepolizumab (100mg, ILO)

Lot No: 12

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Mepolizumab in der Wirkstärke 100mg und in der Darreichungsform Fertigspritze enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:

no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Nilotinib

Lot No: 13

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Nilotinib enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11.

Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Peginterferon beta-1a
Lot No: 14

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland
Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Peginterferon beta-1a enthalten.

II.2.5. Award criteria

Criteria below
Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025
This contract is subject to renewal: yes
Description of renewals:
Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Piribedil
Lot No: 15

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die die Wirkstoffkombination Piribedil enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information**II.2. Description****II.2.1. Title**

Rilpivirin (FTA)

Lot No: 16

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Rilpivirin in der Darreichungsform Filmtabletten enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:

no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Salmeterol (DOS)

Lot No: 17

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Salmeterol in der Darreichungsform Dosieraerosol enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11.

Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Sirolimus

Lot No: 18

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Sirolimus enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Tafamidis

Lot No: 19

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Tafamidis enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information**II.2. Description****II.2.1. Title**

Tafluprost und Timolol

Lot No: 20

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die die Wirkstoffkombination Tafluprost und Timolol enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:

no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Teriflunomid

Lot No: 21

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Teriflunomid enthalten.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Teriparatid (Forsteo®)
Lot No: 22

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland
Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Teriparatid (Forsteo®) enthalten, oder mit diesen nach den Regeln der Substitution austauschbar sind. Dabei werden die Kriterien der Substitution im Rahmenvertrag über die Arzneimittelversorgung nach § 129 Abs. 2 SGB V in der jeweils gültigen Fassung definiert.

II.2.5. Award criteria

Criteria below
Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025
This contract is subject to renewal: yes
Description of renewals:
Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Teriparatid (Livogiva®)
Lot No: 23

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Teriparatid (Livogiva®) enthalten oder mit diesen nach den Regeln der Substitution austauschbar sind. Dabei werden die Kriterien der Substitution im Rahmenvertrag über die Arzneimittelversorgung nach § 129 Abs. 2 SGB V in der jeweils gültigen Fassung definiert.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information**II.2. Description****II.2.1. Title**

Teriparatid (Movymia®_Terrosa®)

Lot No: 24

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: DE Deutschland

Main site or place of performance: bundesweit

II.2.4. Description of the procurement

Vertragsgegenständlich sind Arzneimittel, die den Wirkstoff Teriparatid (Movymia®_Terrosa®) enthalten, oder mit diesen nach den Regeln der Substitution austauschbar sind. Dabei werden die Kriterien der Substitution im Rahmenvertrag über die Arzneimittelversorgung nach § 129 Abs. 2 SGB V in der jeweils gültigen Fassung definiert.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 1,00 EUR

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/10/2023 End: 30/09/2025

This contract is subject to renewal: yes

Description of renewals:

Einmalige Verlängerungsoption um drei Monate bis 31.12.2025.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

Section III: Legal, economic, financial and technical information

III.1. Conditions for participation

III.1.1. Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:

Vervollständigte und unterschriebene Eigenerklärung (Anlage E1) zur Zuverlässigkeit.

Section IV: Procedure

IV.1. Description

IV.1.1. Type of procedure

Open procedure

IV.1.3. Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

IV.1.8. Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: no

IV.2. Administrative information

IV.2.2. Time limit for receipt of tenders or requests to participate

Date: 01/08/2025 Local time: 12:00

IV.2.3. Estimated date of dispatch of invitations to tender or to participate to selected candidates**IV.2.4. Languages in which tenders or requests to participate may be submitted**

German

IV.2.6. Minimum time frame during which the tenderer must maintain the tender

Tender must be valid until: 31/12/2025

IV.2.7. Conditions for opening of tenders

Date: 02/08/2025 Local time: 13:00

Section VI: Complementary information

VI.1. Information about recurrence

This is a recurrent procurement: no

VI.3. Additional information**VI.4. Procedures for review****VI.4.1. Review body**

Official name: Vergabekammer des Bundes beim Bundeskartellamt Bonn

Postal address: Villemombler Str. 76

Town: Bonn

Postal code: 53123

Country: Germany

VI.4.3. Review procedure

Precise information on deadline(s) for review procedures:

Ein Nachprüfungsantrag kann bei der Vergabekammer des Bundes, Bundeskartellamt Bonn, Villemomblerstraße 76, 53123 Bonn, gestellt werden. Der Antrag ist unzulässig, soweit: 1. der Antragsteller den geltend gemachten Verstoß gegen Vergabevorschriften vor Einreichen des Nachprüfungsantrags erkannt und gegenüber dem Auftraggeber nicht innerhalb einer Frist von 10 Kalendertagen gerügt hat; der Ablauf der Frist nach § 134 Absatz 2 GWB bleibt unberührt, 2. Verstöße gegen Vergabevorschriften, die aufgrund der Bekanntmachung erkennbar sind, nicht spätestens bis zum Ablauf der in der Bekanntmachung benannten Frist zur Bewerbung oder zur Angebotsabgabe gegenüber dem Auftraggeber gerügt werden, 3. Verstöße gegen Vergabevorschriften, die erst in den Vergabeunterlagen erkennbar sind, nicht spätestens bis zum Ablauf der Frist zur Bewerbung oder zur Angebotsabgabe gegenüber dem Auftraggeber gerügt werden, 4. mehr als 15 Kalendertage nach Eingang der Mitteilung des Auftraggebers, einer Rüge nicht abhelfen zu wollen, vergangen sind. Satz 1 gilt nicht bei einem Antrag auf Feststellung der Unwirksamkeit des Vertrags nach § 135 Absatz 1 Nummer 2 GWB. § 134 Absatz 1 Satz 2 GWB bleibt unberührt.

VI.5. Date of dispatch of this notice

25/07/2023